Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
JTO Clinical and Research Reports|September 30, 2021
Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural MesotheliomaKazuhiko Nakagawa, Takashi Kijima, Morihito Okada, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 27, 2010
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experienceKatsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, et al.
Lung Cancer (Amsterdam, Netherlands)|August 31, 2023
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutationsTakashi Ninomiya, Nobuhisa Ishikawa, Toshiyuki Kozuki, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 23, 2016
Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer studyKoichi Takayama, Shinji Atagi, Fumio Imamura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2015
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysisKadoaki Ohashi, Kiichiro Ninomiya, Hiroshige Yoshioka, et al.
Pageof 11